Key result
Women initially diagnosed with ductal carcinoma in situ had a significantly lower risk of myocardial infarction (HR 0.64) and stroke (HR 0.77) compared to a matched control group.
Why the study?
Patients with ductal carcinoma in situ are usually diagnosed via cancer screening, suggesting a healthy user effect, but their risk of cardiovascular events and mortality remained unclear.
Does a diagnosis of ductal carcinoma in situ affect the risk of cardiovascular events and mortality in women compared to a matched control group?
Cohort (n=54,960)
Does a diagnosis of ductal carcinoma in situ affect the risk of cardiovascular events and mortality in women compared to a matched control group?
Women diagnosed with DCIS have a lower risk of myocardial infarction and stroke compared to matched controls, likely reflecting a healthy user effect and better comorbidity management.
BACKGROUND: Ductal carcinoma in situ (DCIS) patients are usually diagnosed through cancer screening programs, suggesting a healthy user effect. In this population-based cohort, we assessed the risk of cardiovascular events and mortality in DCIS patients. METHODS: Using the Korean National Health Insurance Service database, 13,740 women, who were initially diagnosed with DCIS between 2007 and 2013, were analyzed. A control group was matched according to age and the year of diagnosis at a 3:1 ratio (n = 41,220). Follow-up was performed until 2016. Subgroup analysis was performed according to the subsequent diagnosis of invasive breast cancer within 1 year: pure DCIS and DCIS+Invasive group. RESULTS: DCIS patients were more likely to have underlying diseases, higher incomes, and to live in urban districts compared to the control group. Women diagnosed of DCIS had lower myocardial infarct risk (hazard ratio [HR] 0.64; 95% confidence interval [CI] 0.46-0.90) and lower stroke risk (HR 0.77; 95% CI 0.60-0.98) compared to the control group. This trend of lower risk was sustained after adjusting for age, income, residence and comorbidities. The mortality rate was similar between the control group and pure DCIS patients but was higher in the DCIS+Invasive group (HR 1.63; 95% CI 1.34-1.98). However, after adjusting for age, income, residence and comorbidities, mortality did not differ between the control group and DCIS+Invasive group (HR 0.99; 95% CI 0.78-1.24). CONCLUSIONS: DCIS patients were at lower risk for MI and stroke compared to a control group despite a higher rate of comorbidities, which may reflect changes in health behaviour. The importance of managing pre-existing comorbidities along with DCIS treatment should be emphasized.
No takes yet. Share an insight, caveat, or question.
Yoo et al. (2021) conducted a cohort in Ductal carcinoma in situ (n=54,960). Ductal carcinoma in situ vs. Matched control group without breast cancer was evaluated on Myocardial infarct (HR 0.64, 95% CI 0.46-0.90). Women initially diagnosed with ductal carcinoma in situ had a significantly lower risk of myocardial infarction (HR 0.64) and stroke (HR 0.77) compared to a matched control group.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: